BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
52 results:

  • 1. Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker outcomes from PNOC003.
    Kline C; Jain P; Kilburn L; Bonner ER; Gupta N; Crawford JR; Banerjee A; Packer RJ; Villanueva-Meyer J; Luks T; Zhang Y; Kambhampati M; Zhang J; Yadavilli S; Zhang B; Gaonkar KS; Rokita JL; Kraya A; Kuhn J; Liang W; Byron S; Berens M; Molinaro A; Prados M; Resnick A; Waszak SM; Nazarian J; Mueller S
    Clin Cancer Res; 2022 Sep; 28(18):3965-3978. PubMed ID: 35852795
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent tp53 mutations and recurrent monosomy 13.
    Pratt D; Abdullaev Z; Papanicolau-Sengos A; Ketchum C; Panneer Selvam P; Chung HJ; Lee I; Raffeld M; Gilbert MR; Armstrong TS; Pytel P; Borys E; Klonoski JM; McCord M; Horbinski C; Brat D; Perry A; Solomon D; Eberhart C; Giannini C; Quezado M; Aldape K
    Acta Neuropathol; 2022 Mar; 143(3):403-414. PubMed ID: 35103816
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.
    Faccion RS; Bernardo PS; de Lopes GPF; Bastos LS; Teixeira CL; de Oliveira JA; Fernandes PV; Dubois LG; Chimelli L; Maia RC
    Cell Oncol (Dordr); 2018 Apr; 41(2):141-157. PubMed ID: 29374392
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
    Marampon F; Megiorni F; Camero S; Crescioli C; McDowell HP; Sferra R; Vetuschi A; Pompili S; Ventura L; De Felice F; Tombolini V; Dominici C; Maggio R; Festuccia C; Gravina GL
    Cancer Lett; 2017 Jul; 397():1-11. PubMed ID: 28342984
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
    De Smet F; Saiz Rubio M; Hompes D; Naus E; De Baets G; Langenberg T; Hipp MS; Houben B; Claes F; Charbonneau S; Delgado Blanco J; Plaisance S; Ramkissoon S; Ramkissoon L; Simons C; van den Brandt P; Weijenberg M; Van England M; Lambrechts S; Amant F; D'Hoore A; Ligon KL; Sagaert X; Schymkowitz J; Rousseau F
    J Pathol; 2017 May; 242(1):24-38. PubMed ID: 28035683
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome.
    Karagkounis G; Stranjalis G; Argyrakos T; Pantelaion V; Mastoris K; Rontogianni D; Komaitis S; Kalamatianos T; Sakas D; Tiniakos D
    J Clin Pathol; 2017 Jul; 70(7):593-599. PubMed ID: 27993946
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote.
    Otani R; Uzuka T; Ueki K
    Jpn J Clin Oncol; 2017 Jan; 47(1):2-6. PubMed ID: 27799281
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
    Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
    Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
    Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma.
    Chen L; Lin ZX; Lin GS; Zhou CF; Chen YP; Wang XF; Zheng ZQ
    Hum Pathol; 2015 Jan; 46(1):120-8. PubMed ID: 25455996
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
    Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
    J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
    Wachsberger PR; Lawrence YR; Liu Y; Rice B; Feo N; Leiby B; Dicker AP
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):573-82. PubMed ID: 24500492
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
    Jaszberenyi M; Schally AV; Block NL; Nadji M; Vidaurre I; Szalontay L; Rick FG
    Oncotarget; 2013 Mar; 4(3):422-32. PubMed ID: 23518876
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
    Preukschas M; Hagel C; Schulte A; Weber K; Lamszus K; Sievert H; Pällmann N; Bokemeyer C; Hauber J; Braig M; Balabanov S
    PLoS One; 2012; 7(8):e43468. PubMed ID: 22927971
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.
    Motomura K; Natsume A; Watanabe R; Ito I; Kato Y; Momota H; Nishikawa R; Mishima K; Nakasu Y; Abe T; Namba H; Nakazato Y; Tashiro H; Takeuchi I; Mori T; Wakabayashi T
    Cancer Sci; 2012 Oct; 103(10):1871-9. PubMed ID: 22747609
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China.
    Yan W; Zhang W; You G; Bao Z; Wang Y; Liu Y; Kang C; You Y; Wang L; Jiang T
    PLoS One; 2012; 7(1):e30339. PubMed ID: 22291938
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
    Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
    Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.